Page 2 - Fatima Cardoso News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aid agencies are failing patients with breast

<p>Patients with breast cancer in conflict zones around the world are being “massively under-served” by governments, UN aid agencies and other non-governmental organisations, Professor Richard Sullivan told the Advanced Breast Cancer Seventh International Consensus Conference. Among people fleeing conflict zones, either displaced within their own country or across borders to other countries, patients with breast cancer are the “single largest group of cancer patients that present to UN agencies and international NGOs,” said Prof. Sullivan, who is director of the Institute of Cancer Policy and co-director of the Centre for Conflict and Health research at King’s College London (UK)</p>

United kingdomIsrael generalRichard sullivanFatima cardosoCentre forGlobal allianceBreast cancer seventh international consensus conferenceBreast unit of the champalimaud clinical centreInstitute of cancerKing college london united kingdomMethod of researchProfessor richard sullivanCancer policyCollege londonSecond world warBreast unit

Latest results from clinical trial show patients with advanced HER2-positive breast cancer live longer on pyrotinib

Latest results from clinical trial show patients with advanced HER2-positive breast cancer live longer on pyrotinib
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesJiong wuBinghe xuFatima cardosoZhimin shaoNational cancer center hospitalGlobal allianceUnion medical collegeBreast unit of the champalimaud clinical centerChinese academy of medical sciencesBreast cancer seventh international consensus conferenceFudan university cancer hospitalSouth americaEastern europeNational cancer centerCancer hospital

Latest results from PHOEBE trial show patient

<p>Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomised clinical trial in China. Presenting the latest results at the Advanced Breast Cancer Seventh International Consensus Conference (ABC 7), Professor Xichun Hu, of Fudan University Cancer Hospital, Shanghai, China, said the researchers had been able to analyse data on overall survival from the trial up to March 15, 2023.</p>

United statesUnited kingdomBinghe xuJiong wuFatima cardosoZhimin shaoMethod of researchFudan university cancer hospitalGlobal allianceNational cancer center hospitalChinese academy of medical sciencesBreast unit of the champalimaud clinical centreBreast cancer seventh international consensus conferenceUnion medical collegeSouth americaEastern europe

Merck shares positive results for Keytruda in early-stage breast cancer

Merck shares positive results for Keytruda in early-stage breast cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Gursel aktanFatima cardosoMerck research laboratoriesMerck coBreast unit of the champalimaud clinical centreBreast unitChampalimaud clinical centre

ICIs Improve pCR Rates in Early ER+/HER2– Breast Cancer

Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor–positive, HER2-negative breast cancer.

City ofUnited kingdomSherene loiFatima cardosoEastern cooperative oncology groupEuropean society for medical oncologyBristol myers squibbPeter maccallum cancer centreInstitute of cancer researchChampalimaud clinical centerEuropean societyRoyal marsden hospitalCancer researchEastern europeBristol myersMerck sharp